Table 4

Thalidomide in patients with newly diagnosed MM

RegimenNo. patientsCR, %Greater than PR, %PFS/EFS/TTP, %OS, %Reference
Dexamethasone       
    TD 235 5 49 50 at 17 mo ND 52*† 
    TD 103 4 63 50 at 22 mo 72 at 24 mo 31* 
    TD 100 10 76 ND ND 32  
    TD 50 ND 64 ND ND 34  
    TD 100 ND 25‡ ND ND 33* 
    TD 136 14 68 50 at 25 mo 50 at 45 mo 35*† 
Melphalan       
    MPT 129 16 76 54 at 24 mo 80 at 36 mo 37* 
    MPT 125 13 76 50 at 28 mo 50 at 52 mo 38* 
    MPT 113 7 62 50 at 24 mo 50 at 45 mo 39* 
Doxorubicin       
    ThaDD 50 34 88 57 at 36 mo 74 at 36 mo 44  
    TAD 193 ND 79-81 ND ND 53* 
    DVd-T 55 36 83 50 at 28 mo ND 25  
    T-VAD doxil 117 15 81 59 at 24 mo 77 at 24 mo 45* 
    T-VAD doxil 39 10 74 55 at 22 mo 74 at 22 mo 40  
Cyclophosphamide, CTD 27 15 89 ND ND 47  
RegimenNo. patientsCR, %Greater than PR, %PFS/EFS/TTP, %OS, %Reference
Dexamethasone       
    TD 235 5 49 50 at 17 mo ND 52*† 
    TD 103 4 63 50 at 22 mo 72 at 24 mo 31* 
    TD 100 10 76 ND ND 32  
    TD 50 ND 64 ND ND 34  
    TD 100 ND 25‡ ND ND 33* 
    TD 136 14 68 50 at 25 mo 50 at 45 mo 35*† 
Melphalan       
    MPT 129 16 76 54 at 24 mo 80 at 36 mo 37* 
    MPT 125 13 76 50 at 28 mo 50 at 52 mo 38* 
    MPT 113 7 62 50 at 24 mo 50 at 45 mo 39* 
Doxorubicin       
    ThaDD 50 34 88 57 at 36 mo 74 at 36 mo 44  
    TAD 193 ND 79-81 ND ND 53* 
    DVd-T 55 36 83 50 at 28 mo ND 25  
    T-VAD doxil 117 15 81 59 at 24 mo 77 at 24 mo 45* 
    T-VAD doxil 39 10 74 55 at 22 mo 74 at 22 mo 40  
Cyclophosphamide, CTD 27 15 89 ND ND 47  

ThaDD indicates thalidomide-pegylated liposomal doxorubicin-dexamethasone; T-VAD doxil, thalidomide-vincristine-pegylated lyposomal doxorubicin; and ND, not determined.

*

Randomized trial.

†

Updated information was presented at the American Society of Clinical Oncology and European Hematology Association Congress.

‡

Very good partial response rate.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal